Compare Citius Pharmaceuticals Inc (CTXR) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Direxion Daily Semiconductor Bull 3X Shares trades at $139.76 (market cap $24.42B). The key difference: Direxion Daily Semiconductor Bull 3X Shares is far larger — about 1793× Citius Pharmaceuticals Inc's market cap, and Direxion Daily Semiconductor Bull 3X Shares is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Direxion Daily Semiconductor Bull 3X Shares for 15 Days on average.
| CTXR | SOXL | |
|---|---|---|
Market Cap | $13.62M | $24.42B |
Volume | 132,438 | 100,232,380 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $300.77 |
52-Week Low | $0.48 | $30.81 |
Typical Hold Time | 17 Days | 15 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
SOXL, the Direxion Daily Semiconductor Bull 3X ETF, is trading at $142.52, down 10.31% with a bearish technical signal. The semiconductor sector faces volatility, with mixed news including recent chip stock rallies and concerns about AI funding and regulatory tariffs. Technical indicators show neutral oscillators but bearish overall momentum, with key support at $134 and resistance at $153.
Outlook remains cautious due to leveraged ETF risks and semiconductor sector volatility. Investment opportunity exists for bullish semiconductor bets amid strong AI demand, but risks include high leverage decay, regulatory headwinds, and crowded trading positioning. Timing is critical given recent sharp rebounds and potential near-term drawdowns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →
